Together AI builds an agentic compiler to try and bring recursive self improvement capabilities to open source models.
Improvement" Take on a Life of Its Own?"If we keep having an AI improve itself, wouldn't explosive evolution (Recursive ...
Recursion Q3 2026 earnings: clinical wins for REC-4881 and REC-1245, Sanofi progress, and cash runway to 2029.
President and Chief Executive Officer - Najat Khan ...
Recursion said it expects to launch its first registrational trial in the second half of this year for its lead candidate REC-4881 based on talks with the FDA, after the oral familial adenomatous ...
On November 2, 2026, four researchers including Rikiya Takehi from MIT CSAIL (Computer Science and Artificial Intelligence ...
RXRX Q3 revenues surge 258.5%, beating estimates as a $10 million Sanofi milestone payment boosts results and advances its ...
Tencent's Hunyuan Research Agent version 2.0 made its debut Monday, claiming to have crossed a threshold that has defined the ambition of AI-for-science research for a decade: instead of solving ...
New Phase 2 REC-4881 data presented at CGA-IGC in an expanded adult population aged 18 years and older show deep, durable polyp burden reductions in FAP, with activity throughout the GI tract and in ...
The latest update is out from Recursion Pharmaceuticals ( (RXRX) ).
A $10 million Sanofi milestone drove revenue 258% higher year over year, beating expectations and showing the AI platform ...
Revenue increase driven primarily by Sanofi collaboration, including a $10.0 million milestone for an immunology small molecule program R&D expense decreased mainly due to non-recurrence of $22.8 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results